Modulation of Social Cognition via Hallucinogens and “Entactogens” by Preller, Katrin H & Vollenweider, Franz X
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Modulation of Social Cognition via Hallucinogens and “Entactogens”
Preller, Katrin H ; Vollenweider, Franz X
Abstract: Social cognition is a fundamental ability in human everyday lives. Deficits in social functioning
also represent a core aspect of many psychiatric disorders. Yet, despite its significance, deficits in social
cognition skills are insufficiently targeted by current treatments. Hallucinogens and entactogens have
been shown to have the potential to modulate social processing. This article reviews the literature on
the influence of hallucinogens and entactogens on social processing in controlled experimental studies in
humans and elucidates the underlying neurobiological and neuropharmacological mechanisms. Further-
more, it identifies current knowledge gaps and derives implications for hallucinogen-assisted treatment
approaches as well as the development of novel medication for trans-diagnostic impairments in social
cognition.
DOI: https://doi.org/10.3389/fpsyt.2019.00881
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-179309
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Preller, Katrin H; Vollenweider, Franz X (2019). Modulation of Social Cognition via Hallucinogens and
“Entactogens”. Frontiers in Psychiatry, 10:881.
DOI: https://doi.org/10.3389/fpsyt.2019.00881
1Edited by: 
Matthew W. Johnson, 
Johns Hopkins University, 
United States
Reviewed by: 
Melissa Ann Herman, 
University of North Carolina 
at Chapel Hill, United States 
Matt Kirkpatrick, 
University of Southern California, 
United States
*Correspondence: 
Katrin H. Preller 
preller@bli.uzh.ch
Specialty section: 
This article was submitted to 
 Psychopharmacology, 
 a section of the journal 
 Frontiers in Psychiatry
Received: 27 June 2019
Accepted: 07 November 2019
Published: 03 December 2019
Citation: 
Preller KH and Vollenweider FX 
(2019) Modulation of Social Cognition 
via Hallucinogens and “Entactogens”. 
 Front. Psychiatry 10:881. 
 doi: 10.3389/fpsyt.2019.00881
Modulation of Social Cognition via 
Hallucinogens and “Entactogens”
Katrin H. Preller * and Franz X. Vollenweider
Neuropsychopharmacology and Brain Imaging, Department of Psychiatry, Psychotherapy, and Psychosomatics, University 
Hospital for Psychiatry Zurich, Zurich, Switzerland
Social cognition is a fundamental ability in human everyday lives. Deficits in social 
functioning also represent a core aspect of many psychiatric disorders. Yet, despite 
its significance, deficits in social cognition skills are insufficiently targeted by current 
treatments. Hallucinogens and entactogens have been shown to have the potential 
to modulate social processing. This article reviews the literature on the influence of 
hallucinogens and entactogens on social processing in controlled experimental studies 
in humans and elucidates the underlying neurobiological and neuropharmacological 
mechanisms. Furthermore, it identifies current knowledge gaps and derives implications 
for hallucinogen-assisted treatment approaches as well as the development of novel 
medication for trans-diagnostic impairments in social cognition.
Keywords: social cognition, psychedelics, serotonin, pharmacology, functional magnetic resonance imaging, 
emotions
INTRODUCTION
Humans are a social species (1). Social processes range from societal matters like politics, to more 
private every-day activities like being successful in a working environment, finding an apartment, 
romantic partnerships, and the use of virtual social networks. To be able to function in this social 
environment, we use capabilities which are subsumed under the term “social cognition” (2). Social 
cognition has been defined as mental processes through which we perceive, think about, and act 
toward other people (3). Critically, deficits in social functioning represent a core aspect and important 
diagnostic criterion of many—if not all—psychiatric disorders (4). Not only do difficulties in social 
interaction abilities increase the risk of developing a psychiatric disorder, but they also contribute to 
the maintenance or worsening of symptoms, as therapeutic processes as well as support seeking and 
re-integration into everyday activities, e.g., work-life, are social activities (4, 5). The importance of 
social cognition has also been recognized by the Research Domain Criteria (RDoC) initiative, which 
defines social processes as one of five trans-diagnostic dimensional constructs critical to human 
behavior and mental disorders (6–8). Yet, deficits in social cognition skills are insufficiently—if at 
all—targeted by current treatment approaches (9).
Hallucinogens are psychoactive substance which induce transient perceptual anomalies and an 
altered state of consciousness. The effect of entactogens is characterized by experiences of oneness 
and emotional openness. Entactogens as well as hallucinogens have been shown to successfully 
modulate social processing in rigorous scientific studies (10–12). This is important for two reasons 
(13): 1) In the search for novel medication for transdiagnostic social dysfunction in psychiatric 
disorders, these substances provide a powerful tool to increase our understanding of the neural 
mechanisms underlying social processing and behavior. Due to their well-investigated receptor 
pharmacology, in particular with regard to hallucinogens, they can identify novel targets for the 
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development of new therapeutics. 2) Given that drug development 
in psychiatry has stagnated for decades, new therapeutic models 
are urgently needed (14). Entactogens and hallucinogens 
have shown promising results in preliminary clinical trials in 
disorders also characterized by social impairments such as 
depression, anxiety, post-traumatic stress disorder (PTSD), and 
autism spectrum disorders (ASD) (15–19). These substances 
could, therefore, represent important adjuncts to psychotherapy 
in psychiatric  disorders.
The first part of this review focuses on the effects of 
hallucinogens and entactogens on social cognition in clinical 
populations (Modulation of Social Cognition in Clinical 
Populations). Acute Effects of Entactogens and Hallucinogens 
on Social Cognition in Healthy Volunteers reviews the acute 
effects of entactogens and hallucinogens on social cognition 
in healthy volunteers. Long-Lasting Effects in Healthy 
Participants provides a summary of long-lasting hallucinogen- 
and entactogen-induced effects on social cognition, and 
Neuropharmacological Underpinnings of Alterations in Social 
Cognition Induced by Hallucinogens and Entactogens explores 
the neuropharmacological basis of these modulatory effects. 
This chapter is particularly important for informing the 
development of novel therapeutics targeting socio-cognitive 
deficits in psychiatric disorders. Complimentary to the 
work reviewed here, there is a broad body of literature on 
the effects of these substances on social cognition in animals 
(20). However, these studies are beyond the scope of this 
review and so will not be discussed here. Furthermore, 
this review focuses on experimental and controlled studies 
in humans and will not include literature on survey data 
or studies completed with recreational drug users. This 
review mainly discusses effects induced by two entactogens, 
3,4-methylenedioxymethamphetamine (MDMA) and gamma-
hydroxybutyrate (GHB), and two hallucinogens, lysergic 
acid diethylamide (LSD) and psilocybin. GHB, sometimes 
also referred to as liquid ecstasy, has been associated with 
the group of entactogens (21). However, it is important to 
note that the neuropharmacological mechanisms underlying 
GHB’s psychotropic effects differ strongly from MDMA 
and serotonergic hallucinogens (22). Yet, given that GHB 
has been reported to be used recreationally for its prosocial 
effects, empirical studies on GHB are included in this review. 
Experimental research on the influence of other hallucinogens 
and entactogens on social functioning in humans is currently 
lacking and should be investigated in future studies.
MODULATION OF SOCIAL COGNITION IN 
CLINICAL POPULATIONS
Alterations in social processing may be important modulators 
of the clinical efficacy of entactogens and hallucinogens. 
MDMA-assisted psychotherapy has been shown to reduce social 
anxiety in autistic adults for up to 6 months after treatment 
(18). Twelve out of 19 PTSD patients interviewed 1 year 
after they had completed MDMA-assisted therapy reported 
enhanced relationships and social functioning as a benefit from 
participating in the treatment (23). The patients described 
increased empathy, communication with other people, and 
improved relationships with friends and family (23). These 
pro-social effects may be particularly important for preventing 
relapse and increasing the long-term success of MDMA-assisted 
therapy, since they may reduce social withdrawal and promote 
support seeking.
Recent preliminary studies on the efficacy of psilocybin 
in mood disorders and addiction have also shown promising 
results (16, 17, 24, 25). In an open-label pilot study, 12 out 
of 15 treatment-seeking smokers were nicotine abstinent 
6 months after two to three administrations of psilocybin 
(26). In a follow-up interview participants identified social 
factors, i.e., smoking as a way of connecting with other 
people, that contributed to their addiction and reported 
psilocybin-induced feelings of love and connection with 
their environment and other people as important for quitting 
smoking (27). Furthermore, some patients described engaging 
more in prosocial and altruistic activities after their psilocybin 
sessions (27), raising the possibility that psilocybin may 
have re-instated social reward processing helping patients to 
overcome their addiction.
Furthermore, psilocybin has been shown to have beneficial 
effects in an open-label feasibility study in patients suffering 
from treatment-resistant depression (16). Three months 
after treatment, patients showed increases in extraversion 
and openness scores (28). Furthermore, Lyons & Carhart-
Harris (29) reported a slight, but non-significant decrease in 
authoritarian political views in seven depressed patients 7–12 
months after treatment with psilocybin. In this study, objective 
tests of emotion recognition and processing were conducted. 
On the FERT, the speed of emotional face recognition was 
increased 1 week after psilocybin treatment, an effect that 
correlated with reduced anhedonia (30). In contrast to 
results obtained during the acute effects of psilocybin in 
healthy participants (see Empathy, Mentalizing, and Emotion 
Recognition), amygdala reactivity was increased in response 
to fearful faces in treatment-resistant depressed patients the 
morning after psilocybin administration (31). It is therefore 
possible that psilocybin facilitates the processing of negative 
experiences acutely via a reduction of amygdala reactivity, 
rendering them more accessible and bearable. This may lead 
to increased reactivity and emotional processing post-acutely. 
However, increased amygdala reactivity toward fearful faces 
was measured prior to any psychological integration work (31). 
Therefore, long-term effects of psilocybin on amygdala reactivity 
and its clinical relevance still need to be determined in future 
studies. Yet, the same patients reported that they experienced a 
sense of disconnection from others as particularly distressing 
before psilocybin-assisted treatment (32). After treatment, 
many reported to be able to “re-connect” with family members, 
friends, strangers, and even people who had wronged them. 
Patients identified this increased connection as one of two main 
change processes in relation to treatment (32), supporting the 
idea that the influence of hallucinogens on social cognition and 
behavior may be an important mechanism underlying their 
clinical efficacy.
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ACUTE EFFECTS OF ENTACTOGENS 
AND HALLUCINOGENS ON SOCIAL 
COGNITION IN HEALTHY vOLUNTEERS
Acutely, MDMA has been described as a prototypical entactogen 
and is recreationally used for its prosocial effects (20). It is 
also the substance most widely studied in relation to social 
perception. More recently, there has been growing interest the 
effects of hallucinogens, in particular LSD and psilocybin, 
on social cognition. Studies showed that, like MDMA, both 
psilocybin and LSD, significantly modulate social processing and 
have acute pro-social effects (11, 12, 33, 34). Recreationally, low 
doses of GHB have been reported to be used to increase sexual 
arousal (35).
Self-reported pro-social effects measured in scientific studies 
include increased trust and closeness to others. For example, after 
the administration of 1.5 mg/kg MDMA participants reported a 
significantly increased desire to engage in social activities (36), 
as well as increased pleasantness of affective social touch (37). 
When given the opportunity, MDMA participants also spent 
more time interacting with others, particularly after a low dose 
(0.5 mg/kg) (38). Furthermore, MDMA (125 mg) increased the 
subjective experience of being close to others and trusting others 
by approximately 25% during peak effects (10, 39). Increases in 
closeness and trust during peak effects after LSD administration 
(200 μg) have been shown to be in a similar range (33, 40). 
GHB (20 mg/kg) has been reported to increase the tendency to 
talk (41).
The following chapters provide a detailed overview of the 
acute effects of MDMA, GHB, psilocybin, and LSD on different 
objective measures of social cognition, including empathy, 
mentalizing, and emotion recognition, moral and altruistic 
behavior, social rejection sensitivity, social influence, sexual 
arousal and perception of romantic relationships, and social 
influence processing. A summary of the results is provided 
in Figure 1.
Empathy, Mentalizing, and 
Emotion Recognition
Empathy has been defined as the ability to vicariously experience 
and/or understand the affect of others, and is thought to be 
critical for prosocial behavior (42). Empathy is impaired in a 
number of psychiatric disorders, including depression, addiction, 
borderline personality disorder, and psychopathy (43–46). 
However, empathy is a multidimensional construct, comprising 
of both emotional and cognitive components (43). The emotional 
aspect of empathy describes a person’s emotional reaction to 
another’s emotional state, i.e., the ability to feel what another 
person feels (47). Cognitive empathy refers to the ability to take 
another person’s perspective and the understanding of another 
person’s mental state, without necessarily being in the same 
affective state (47). Thus, cognitive empathy strongly overlaps 
FIGURE 1 | Overview of social processes modulated by entactogens and hallucinogens. 1Measured with the Multifaceted Empathy Test. 2Only assessed after the 
administration of low doses (≤26 µg). 3Assessed in male participants only. 4In men and when directed toward friends, but not strangers.
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with the concepts of affective theory of mind, mentalizing, and 
emotion recognition (48).
Various tasks have been applied to study empathy after 
the administration of hallucinogens and entactogens. The 
Multifaceted Empathy Task [MET (49)] captures both, emotional 
and cognitive empathy. Participants are asked to rate emotional 
pictures on induced emotional concern and arousal (emotional 
empathy). Furthermore, participants are asked to identify the 
mental state the person depicted is in (cognitive empathy). 
Additionally, cognitive empathy has been assessed using tasks 
such as the Movie for the Assessment of Social Cognition 
(MASC), the Reading the Mind in the Eyes Task (RMET), as 
well as different versions of the Facial Emotion Recognition Task 
(FERT). The MASC is a video-based test of mentalizing and 
therefore represents the most ecologically valid test of cognitive 
empathy (50). The REMT, like the MET, requires participants to 
infer the mental state of a person in a photograph by choosing 
which of four words provided along with the picture describes 
best what the person in the picture is feeling. However, while the 
MET displays everyday life situations conveying information on 
emotional mental states via facial expression, body language, and 
context, the RMET focuses exclusively on the eye region. The 
FERT constitutes a further emotion recognition task. In most 
versions, different intensities of facial emotions are presented 
making it possible to calculate the intensity that is necessary for 
an emotion to be detected correctly, but unlike the MASC and 
MET does not depict whole sceneries.
Various studies have consistently shown that MDMA 
modulates emotional empathy, assessed using the MET (49). 
An overview of all results is presented in Table 1. One hundred 
twenty-five milligrams as well as 75 mg MDMA increased 
emotional empathy (10, 51, 52). In two studies this increase was 
particularly pronounced in response to positive stimuli and in 
male participants (10, 51). A third study did not find an influence 
of valence (52). A pooled analyses of these data confirmed the 
MDMA-induced increase in emotional empathy in particular 
for positive emotions, but did not find an influence of sex or 
trait empathy (62). However, one study, showed contrary results 
reporting no influence of 100 mg of MDMA on emotional 
empathy in male participants (53).
Like MDMA, LSD has been shown to increase emotional 
empathy, assessed with the MET. LSD dose-dependently 
increased emotional empathy with significant effects at 200 μg 
(33). In line with results obtained under the influence of MDMA, 
enhanced emotional empathy under LSD was not modulated by 
trait empathy (12). However, while the LSD-induced increase 
in emotional empathy was particularly pronounced for positive 
stimuli, the psilocybin-induced (0.215 mg/kg) increase in 
emotional empathy was shown to be independent of valence 
(12). In contrast to MDMA and LSD, GHB (20 mg/kg) was not 
shown to affect emotional empathy (41).
While the increase in emotional empathy after the 
administration of MDMA, psilocybin, and LSD is mostly 
consistent across studies and substances, their effect on cognitive 
TABLE 1 | Effects of entactogens and hallucinogens on empathy, mentalizing, and emotion recognition.
Drug Doses Emotional 
empathy
Cognitive empathy Emotion recognition References
MET MET MASC RMET FERT/
Affective 
Bias Task
Emotional 
face 
reactivity
MDMA 75 mg ↑1 – – – – 51, 52
MDMA 100 mg – – ↓2 53
MDMA 125 mg ↑1 – ↑↓3 ↓2 10, 39, 54
MDMA 0.75 mg/kg – – – 36, 37, 55, 56
MDMA 1.5 mg/kg – ↓2 ↑4 36, 37, 55, 56
GHB 20 mg/kg – – -– 41
Psilocybin 0.115 mg/kg ↓5 57
Psilocybin 0.160 mg/kg ↓6 58
Psilocybin 0.170 mg/kg ↓7 59
Psilocybin 0.215 mg/kg ↑ – ↓2 12, 60
LSD 100 μg – ↓ ↓2 ↓8 33, 61
LSD 200 μg ↑9 ↓ ↓2 33
1Predominantly in male participants and for positive stimuli.
2For negative emotions.
3Decreases for negative emotions, increases for positive emotions.
4Increased zygomatic (“smile”) muscle activity in response to happy facial expressions, increased visual attention to happy faces.
5Reduced response to negative emotions (EEG).
6Connectivity changes during negative and positive facial emotion processing (fMRI).
7Reduced neural response to negative and positive facial emotions (EEG).
8Reduced neural response to negative emotions (fMRI).
9For positive stimuliMET, Multifaceted Empathy Test; MASC, Movie for the Assessment of Social Cognition; FERT, Facial Emotion Recognition Task; empty cells indicate 
that this measure was not collected.
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empathy is less clear. Performance on the MASC has been studied 
after the administration of GHB (20 mg/kg), but did not reveal 
significant results (41). Similarly, MDMA (75 mg) administration 
did not induce significant modulations on the MASC (61). In 
line with this, MDMA (75, 100, & 125 mg), GHB (20 mg/kg), 
and psilocybin (0.215 mg/kg) did not affect cognitive empathy 
on the MET (10, 12, 51–53, 62). In contrast, LSD (100 and 200 
μg) decreased cognitive empathy on the MET (33). In line with 
results obtained with the MET, two studies did not find an effect of 
MDMA (0.75 mg/kg, 1.5 mg/kg, and 75 mg) on the RMET (52, 55). 
However, a third study reported that MDMA (125 mg) increased 
the recognition of positive and decreased the identification of 
negative emotions (54). Psilocybin (0.215 mg/kg) decreased the 
recognition of negative emotions on the RMET (60).
Testing the performance on the FERT, Schmid et al. (57) did 
not find any effects after the administration of 75 mg MDMA. 
However, a 100 mg dose of MDMA decreased the accuracy of 
identifying fear and anger on a similar task (53). Additionally, 
a 125 mg dose of MDMA impaired the identification of fearful 
faces (39) and of fearful, angry, and sad faces, particularly in 
women, in a second study (10). This is in line with further results 
showing that 1.5 mg/kg but not 0.75 mg/kg MDMA decreased the 
accuracy of fear recognition (55) and anger and fear recognition 
(36). Furthermore, Wardle and de Wit (56) reported that MDMA 
(1.5 mg/kg) increased the intensity required to identify anger. 
No effects were found for a lower dose (0.75 mg/kg) or other 
emotions including fearful facial expressions. In the same study, 
MDMA (1.5 mg/kg) reduced corrugator (“frown”) muscle activity 
to happy facial expressions in female participants and increased 
zygomatic (“smile”) muscle activity to happy facial expressions 
in all participants. No effects were found while viewing negative 
emotions (56). When presented with pairs of faces (one neutral 
face and one emotional expression face) 1.5 mg/kg, but not 0.75 
mg/kg MDMA, increased visual attention to happy faces, but not 
to negative emotions (37).
Emotion recognition has also been investigated after the 
administration of hallucinogens. Emotional face identification 
was not altered by small doses (“microdoses,” 6.5, 13, and 26 
μg) of LSD (63). However, psychedelic doses of LSD (100 and 
200 μg) impaired the recognition of fearful and sad faces on the 
FERT (33). In line with this, the administration of LSD (100 μg) 
reduced the neural response to fearful vs. neutral faces in the left 
amygdala and the right medial frontal cortex (61). Psilocybin 
(0.115 mg/kg) also reduced the subjective discrimination 
between fearful and neutral faces and the encoding of fearful 
faces measured with EEG expressed by reduced N170 responses 
(57). The processing of happy faces was not affected (57). 
However, after the administration of 0.170 mg/kg two time 
periods of psilocybin-induced modulation of emotional face 
processing were identified: during the 168–189 ms interval 
decreased activity in response to both neutral and fearful faces 
within limbic areas, including amygdala and parahippocampal 
gyrus, and the right temporal cortex was observed, and over 
the 211–242 ms interval reduced activity in response to happy 
faces within limbic and right temporo-occipital brain areas 
was observed (59). Investigating the effect of psilocybin (0.160 
mg/kg) during the discrimination of angry, happy, and fearful 
vs. neutral faces on amygdala seed-to-voxel connectivity via 
functional magnetic resonance imaging (fMRI) showed that 
psilocybin decreased the connectivity between the amygdala and 
the striatum during angry face discrimination. The connectivity 
between the amygdala and the frontal pole was decreased during 
happy face discrimination. No effect was observed during 
discrimination of fearful faces (58).
In sum, both hallucinogens and the entactogen MDMA, 
but not GHB, have been shown to acutely increase emotional 
empathy in controlled experimental trials. This effect seems to be 
more pronounced for positive emotions, in particular after the 
administration of MDMA. Cognitive empathy and mentalizing, 
i.e., the ability to correctly infer another person’s mental state, 
was mostly unchanged by hallucinogens and entactogens. 
Reduced emotional but preserved cognitive empathy has been 
reported in patients suffering from substance use disorders (46). 
Facilitating the reconnection with their social environment 
via increased emotional empathy may therefore contribute to 
clinical efficacy of hallucinogens shown in preliminary studies 
with addicted patients (24, 26). In contrast to psilocybin and 
MDMA, LSD decreased the correct interpretation of ecologically 
valid stimuli (33) and psilocybin decreased the ability to infer 
negative emotions from the eye region (60). In one study, MDMA 
decreased the decoding of negative emotions from the eye 
region, while at the same time increasing this ability for positive 
stimuli (54). These results are in line with reduced recognition 
and processing of predominantly negative emotional faces after 
the administration of higher doses of MDMA and at all doses 
tested (low-high) of psilocybin and LSD. The increased empathy 
for positive emotions and decreased recognition of negative 
emotions shown in these studies is in line with the interpretation 
by Bedi et al. (55) that a decreased ability to identify negative 
emotions might facilitate social approach behavior and thus 
social interaction. This effect might be clinically relevant, since it 
may reduce social withdrawal behavior and improve the patient-
therapist relationship during hallucinogen-assisted treatment. 
However, this hypothesis remains to be tested by future studies.
Moral and Altruistic Behavior
Moral and altruistic behaviors are fundamental for a 
functioning society (64). Despite its significance, to date the 
neuropharmacology of moral behavior has been scarcely 
investigated. Using moral dilemma tasks, it has been shown that 
neither MDMA (75 mg) nor psilocybin (0.215 mg/kg) influenced 
moral decision making (12, 51). However, no other studies have 
investigated the influence of hallucinogens or entactogens on 
moral behavior.
To understand the effects of hallucinogens and entactogens on 
altruistic behavior, most studies implemented resource allocation 
tasks. On the Social Value Orientation Test (SVO) participants 
act altruistically when choosing an option that maximizes the 
allocation for another person. While MDMA did not change 
behavior on the SVO when administered in a lower dose (75 
mg) (51), male participants made more altruistic choices after 
the administration of 125 mg MDMA (10). No effect was found 
for female participants, potentially because they already showed 
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high altruistic behavior following placebo administration (10). 
Another study employed a similar paradigm, the Welfare Trade-
Off Task, and reported that participants showed more altruistic 
behavior after the administration of 1 mg/kg MDMA, but only 
if the other person was a friend, not a stranger (65). This is in 
line with another study showing that MDMA (75 mg) did not 
influence trust or reciprocity during a Trust Game played with 
an unknown partner (52). However, the effects of MDMA on 
trust and reciprocity toward a close friend were not assessed 
in this study. Modulation of altruistic behavior after MDMA 
administration therefore seems to depend on dose, gender, and 
social proximity. Increased altruistic behavior on the SVO was 
also induced by LSD (100 and 200 μg, combined groups) (33). 
After GHB (20 mg/kg) administration, participants also showed 
more altruistic behavior on the SVO and a Charity Donation 
Task, but only after participants who scored high at baseline 
were excluded from the analysis (41). No effect was found for 
reciprocity during a Trust Game after GHB administration (41).
Investigating allocation behavior in more reciprocal tasks, 
Gabay et al. (66) showed that psilocybin (2 mg, i.v.) as well 
as MDMA (100 mg) reduced altruistic punishment, i.e., 
punishment of social norm violations which are costly to the 
self, in the Ultimatum Game in male participants. Furthermore, 
Gabay et al. (53) found that male participants behave more 
cooperatively when interacting with trustworthy partners and 
show greater recovery from breaches of trust during an iterated 
prisoner’s dilemma after the administration of MDMA (100 
mg). However, results on economic allocation games are often 
difficult to interpret, especially in studies investigating the 
effects of substances that induce altered states of consciousness. 
While data on reward sensitivity were collected in the MDMA 
condition, this was not the case for the psilocybin condition 
(66). It is conceivable that psilocybin may alter sensitivity to 
financial rewards, rendering the interpretation of allocation tasks 
involving monetary rewards more challenging.
In sum, hallucinogens and entactogens have been shown to 
increase altruistic behavior. However, it is important to bear in mind 
the following caveats: these substances may also alter sensitivity to 
financial rewards; increases in altruistic behavior may occur only in 
participants with low altruism at baseline; and finally increases in 
altruistic behavior may occur only when directed toward a friend. 
A summary is presented in Table 2. Even though the effects of 
hallucinogens and entactogens on prosocial behavior seem to be 
complex and dependent on factors such as social proximity and 
baseline altruism, they may be important within a therapeutic 
framework as increases in altruism may support reconnection with 
the patients’ social environment. In contrast to altruistic behavior, 
no effect has been found on moral decision making as measured 
with moral dilemma tasks. It is conceivable that hallucinogens 
and entactogens do not impact moral behavior, yet it is also 
possible that higher doses are needed to change moral decision 
making. Additionally, it is noteworthy that moral dilemmas often 
include violent and negative actions and outcomes. Yet, it has 
been shown that hallucinogens reduce the processing of negative 
stimuli. It is therefore possible that moral dilemmas were less 
salient after psilocybin administration. Lastly, post-acute effects of 
hallucinogens and entactogens have not been examined yet. It may 
be possible that changes in moral behavior only occur post-acutely.
Social Rejection Sensitivity
Increased sensitivity to social rejection and exclusion is observed 
in many psychiatric disorders (67–69). At the same time, 
psychiatric patients frequently encounter social rejection (70). 
Normalizing increased rejection sensitivity could therefore be 
clinically relevant to avoid being trapped in a vicious circle that 
ultimately leads to social withdrawal, reduced support, and the 
worsening of clinical symptoms.
A commonly used paradigm to investigate the reaction to 
social rejection is called “Cyberball.” This paradigm consists of 
TABLE 2 | Effects of entactogens and hallucinogens on moral and altruistic behavior.
Drug Doses Moral 
behavior
Altruistic behavior Reciprocity/trust References
Moral 
Dilemmas 
Task
Social 
value 
Orientation 
Test
welfare 
Trade-Off 
Task
Charity 
Donation 
Task
Ultimatum 
game
Trust 
game
Prisoner’s 
dilemma
MDMA 75 mg – – – 51, 52
MDMA 1 mg/kg ↑1 65
MDMA 100 mg ↑2 ↑2 53, 66
MDMA 125 mg ↑2 10
GHB 20 mg/kg ↑3 ↑3 – 41
Psilocybin 0.215 mg/kg – 12
Psilocybin 2 mg, i.v. ↑2 66
LSD 100 and 200 
µg
33
1Only toward friends, not strangers.
2Only in male participants.
3Only after participants were excluded who scored high at baseline 
empty cells indicate that this measure was not collected.
December 2019 | Volume 10 | Article 881Frontiers in Psychiatry | www.frontiersin.org
Hallucinogens and Social CognitionPreller and Vollenweider
7
an interactive virtual ball-tossing game that simulates a real-
life interactive experience of social exclusion (71). While in the 
beginning participants are usually equally involved in the game, 
one player is eventually excluded. In most studies, the participants 
themselves are the ones who are excluded and therefore rejected 
by the other players, which reliably induces feelings of “social 
pain” (72).
MDMA (0.75 and 1.5 mg/kg) has been shown to reduce the 
effect of social rejection on self-reported lower mood and self-
esteem. The higher dose of MDMA (1.5 mg/kg) additionally 
increased the perceived percentage of throws received in the 
rejection condition (73). However, no modulatory effects of 
MDMA (75 mg/kg) on the reaction to social exclusion were found 
when only one of three players was excluding the participant (52). 
Social exclusion often leads to social stress (74). Yet, MDMA (0.5 
and 1.0 mg/kg) did not alter the response to social stress in the 
Trier Social Stress Test (75).
The effect of LSD on social rejection induced by the 
Cyberball game has so far only been tested with very low doses 
(“microdoses”). Bershad et la. (63) (in press) reported that 
6.5, 13, and 26 μg did not modulate the perceived number of 
received ball throws or influenced mood responses to rejection. 
Preller et al. (11) combined the Cyberball paradigm with fMRI 
and MRS measurements to study the effects of psilocybin on 
social rejection processing. After psilocybin (0.215 mg/kg) 
administration, participants reported a reduced feeling of social 
exclusion, while at the same time no significant differences were 
found between placebo and psilocybin with regard to perceived 
number of received ball throws. Furthermore, the neural 
response to social exclusion was decreased in the dorsal anterior 
cingulate cortex and the middle frontal gyrus, key regions for 
social pain processing. This reduction in the “social pain signal” 
was significantly correlated with decreased aspartate content. 
Furthermore, it correlated with psilocybin-induced alterations 
in self-processing, i.e., experience of unity (11). This is in line 
with a study showing that hallucinogen-induced alterations 
in self-processing and social cognition are intertwined (34). 
Such findings may be of particular interest in the treatment of 
psychiatric disorders characterized by an increased self-focus 
like depression (76). Hallucinogen-induced alterations in self-
processing such as the experience of unity may reduce self-focus 
and concurrently improve social functioning.
In sum, psilocybin has been shown to attenuate the processing 
of negative stimuli which extends to negative social interaction 
(11, 77). While participants under the influence of psilocybin 
were able to correctly guess the number of received ball throws 
indicating that they were fully aware of being excluded, their 
self-reported emotional response was decreased in line with 
a reduction in the “social pain signal” in the anterior cingulate 
cortex (11). However, MDMA reduced self-reported negative 
effects of social exclusion, but also increased perceived ball throws, 
potentially indicating reduced awareness of social exclusion (73). 
It is therefore possible that both substances reduce the processing 
of social rejection via different mechanisms. It is also conceivable 
that reducing rejection sensitivity is critically involved in the 
potential therapeutic effects of entactogens and hallucinogens, in 
particular with respect to therapist–patient interaction. However, 
this hypothesis has not yet been tested in clinical populations. 
Finally, the effects of entactogens and hallucinogens on social 
rejection processing other than psilocybin and MDMA still need 
to be investigated in future studies.
Sexual Arousal and Perception of 
Romantic Relationships
Engaging in romantic relationships and sexual behavior is an 
intimate social process and disturbances of close inter-personal 
relationships are prominent in psychiatric disorders (78). Yet, 
only a few neuropsychopharmacological studies have so far 
explored this aspect of social cognition. To date, no studies have 
experimentally investigated how hallucinogens influence sexual 
arousal or the perception of romantic relationships. Studies on 
the effects of entactogens on these processes are more common. 
After the administration of MDMA (125 mg), participants 
reported increased sexual arousal and desire (39). Furthermore, 
participants used more sexual and social words when discussing 
a close personal relationship after the administration of 1.5 mg/
kg MDMA (79). On the Sexual Arousal Task, a computerized task 
presenting neutral as well as implicit and explicit sexual pictures, 
participants treated with MDMA (75 mg) sought to increase the 
presentation time of implicit sexual stimuli, however they did 
not report alterations in sexual arousal while viewing the images 
(80). Furthermore, no effect was found on the evaluation of 
romantic relationships of others (80) or on attractiveness ratings 
(36). Together, these results suggest only subtle, subjective 
effects of MDMA on sexual arousal and perception of intimate 
relationships, but may reflect an increased willingness to disclose 
personal information (79).
GHB has been reported to have pronounced effects on self-
reported sexual arousal (81). In an experimental setting, GHB 
(20 and 35 mg/kg) dose-independently increased self-reported 
sexual arousal and desire (82). Furthermore, participants 
reported more sexual arousal while viewing erotic as well as 
neutral stimuli (82). Together, these results point to a prosexual 
effect specific for GHB. However, more research is needed to also 
determine the effects of hallucinogens on sexual arousal and the 
perception of intimate relationships.
Social Influence Processing
Very little research has been conducted to investigate the effect 
of hallucinogens and entactogens on suggestibility and social 
influence processing, despite the fact that it is highly relevant 
for therapeutic interaction. So far, only two studies have 
been conducted, both investigating the influence of LSD on 
suggestibility (83, 84). The first study, which was limited by a small 
sample of 10 healthy volunteers, showed that LSD (40–80 μg, i.v.) 
enhances suggestibility on the Creative Imagination Scale, while 
Cued Imagery remained unaffected (83). A second study showed 
that LSD (100 μg, p.o) increases adaptation to opinions expressed 
by a norm group, but only if those opinions were not too different 
from the participants own (84). Furthermore, this study showed 
that increases in blood oxygen level-dependent signal in medial 
prefrontal regions were associated with altered social feedback 
processing. It is therefore conceivable that hallucinogens influence 
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how participants process social feedback and how they integrate 
this feedback to subsequently make decisions. This finding 
has direct clinical relevance for therapists working with these 
substances within the framework of hallucinogen-assisted 
therapy. Furthermore, the impact of alterations in social feedback 
processing in a clinical setting should be evaluated and therapists 
trained accordingly.
LONG-LASTING EFFECTS IN HEALTHY 
PARTICIPANTS
While it has repeatedly been shown that hallucinogens 
increase the personality trait openness (85, 86), experimental 
studies investigating the long-term effects of entactogens and 
hallucinogens on social cognition and behavior remain scarce.
It has been reported that recreational MDMA users showed 
increased cognitive, but not emotional, empathy compared 
to controls on the MET and the MASC (87, 88). Furthermore, 
they exhibited less-self-serving behavior on a money allocation 
task played with a stranger (87). Interestingly, these social 
functions were not influenced by acute administration of 
MDMA in controlled studies (10, 51, 52). However, cross-
sectional investigations in recreational drug users have to 
be interpreted with caution as they do not allow for causal 
inference. It is therefore possible that MDMA has post-acute 
positive effects on cognitive empathy and altruistic behavior, but 
it is also conceivable that people with high cognitive empathy 
and prosocial motivation are more prone to recreationally 
use MDMA. To test these hypotheses, the long-term effects of 
MDMA on social cognition in healthy individuals need to be 
investigated in future experimental and controlled studies.
Self-reported increases in interpersonal closeness and 
positive/altruistic social effects were reported 1, 2, 6, and 14 
months after one and two administrations of psilocybin (89–92). 
Self-reported increases in positive/altruistic social effects were 
also shown 12 months after the administration of LSD in healthy 
participants (93). However, the personality trait openness was 
not influenced by LSD administration in this study (93).
Objective data on the long-term effects of hallucinogens on 
social processes is still scarce. Mason et al. (94) reported that 
emotional empathy on the MET was increased the morning after 
a psilocybin retreat. This increase was still significant after seven 
days, but only for negative emotions. Given the lack of further 
data on objective long-term effects, future studies are needed to 
evaluate whether hallucinogens and entactogens have a lasting 
impact on social processes.
NEUROPHARMACOLOGICAL 
UNDERPINNINGS OF ALTERATIONS 
IN SOCIAL COGNITION INDUCED BY 
HALLUCINOGENS AND ENTACTOGENS
Understanding the neuropharmacological underpinnings of 
alterations in social cognition induced by hallucinogens and 
entactogens is vital to accelerate the development of novel 
medication for transdiagnostic social dysfunction in psychiatric 
disorders. MDMA, GHB, psilocybin, and LSD engage with 
various targets in the brain. To assess the neuropharmacological 
mechanisms underlying the prosocial effects of these substances, 
studies have investigated the neuroendocrinology after drug 
administration, the effects of these substances after blocking 
specific receptors or transporters, and have compared the effects 
between substances with different mechanisms of action.
MDMA interacts with numerous transporters and receptors 
in the brain. It releases 5-HT, NE, and, to a lower extent, DA 
from nerve terminals via action on monoamine transporters, 
and increases plasma levels of oxytocin, prolactin, and cortisol 
(10). MDMA is also a low-potency partial agonist of 5-HT 
receptors (95–97). GHB has direct agonist effects on GHB- 
and GABAB-receptors and neuromodulatory properties on 
glutamate, dopamine, serotonin, norepinephrine, and cholinergic 
transmission (22). Furthermore, GHB has been shown to increase 
plasma progesterone, but not oxytocin or testosterone levels (41).
Molecular studies have shown that the psychoactive metabolite 
of psilocybin, psilocin, binds to various serotonin receptors (PDSP 
database: https://pdsp.unc.edu/databases/kidb.php). Psilocin has 
high affinity and agonist activity on the 5-HT2A receptor and this 
receptor subtype is critically implicated in psilocybin-induced 
effects (98). Additionally, recent evidence in humans also 
suggests the involvement of the 5-HT1A receptor in  mediating 
the effects of psilocybin (99). LSD has predominantly agonist 
activity at 5-HT2A/C, −1A/B, −6, and −7 and dopamine D2 and 
D1 receptors. Administering the 5-HT2A receptor antagonist 
ketanserin before LSD administration has been shown to block 
LSD-induced effects, implicating activity on this receptor as vital 
for its effects (100).
To date, only few studies have investigated the pharmacology 
of MDMA-induced alterations in social cognition via blocking 
specific receptors. Kuypers et al. (52) showed that the mixed 
beta-adrenoreceptor blocker/5-HT1A antagonist pindolol did 
not block MDMA-induced increases in emotional empathy. A 
further study showed that neither duloxetine, which inhibits 
MDMA-induced monoamine transporter-dependent serotonin 
and norepinephrine release, reboxetine, which inhibits MDMA-
induced norepinephrine release, nor clonidine, which inhibits 
MDMA-induced transporter-independent vesicular release of 
norepinephrine, blocked the observed increases in decoding 
accuracy for positive and impaired decoding accuracy for 
negative stimuli on the RMET after MDMA administration (54). 
However, duloxetine was most effective in reducing the acute 
subjective MDMA effects, implicating the serotonin system as a 
key mechanism of action (54). This is in line with results reported 
by Kuypers et al. (101) showing that an MDMA-induced 
reduction of arousal in response to negative sounds was blocked 
by the 5-HT2A receptor antagonist ketanserin.
The neuropeptide oxytocin has repeatedly, although not 
unanimously, been related to social behavior (102). Therefore, 
MDMA-induced increases in oxytocin levels are another 
candidate mechanism potentially underlying MDMA’s prosocial 
effects. However, so far, no study investigating the relationship 
between MDMA-induced effects and oxytocin plasma levels has 
found significant correlations with regard to social processing 
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and behavior. For example, increases in emotional empathy, 
impaired identification of negative emotions, enhanced decoding 
of positive facial expressions, and increased altruistic choices 
after MDMA administration were not related to oxytocin plasma 
levels or other neuroendocrine effects (10, 51, 52, 54). In line 
with this, comparing the effects of MDMA directly with oxytocin 
showed differential effects of the two substances. Kuypers 
et al. (52) investigated the effects of MDMA and oxytocin in a 
within-subject design and reported that while MDMA increased 
emotional empathy, oxytocin did not affect measures of empathy 
or other social cognitive outcomes. A further study reported that, 
in contrast to MDMA, intranasal oxytocin enhanced recognition 
of negative emotional faces (36). Additionally, only modest 
correlations between the effects of MDMA and oxytocin in the 
same individuals were found. The effects of MDMA (1.5 mg/kg) 
on social cognition were also substantially more pronounced 
than the ones induced by oxytocin (40 IU) (36). Together, these 
results provide limited support for the hypothesis that increases 
in oxytocin levels underlie the prosocial effects of MDMA. This 
is in contrast to animal studies indicating that oxytocin plays an 
important role in MDMA-related social effects (103, 104). Being 
beyond the scope of the current review, future work should 
address these discrepancies between human and animal data.
Additionally, a number of studies have compared the 
effects of MDMA with other amphetamines as well as with 
modafinil. These studies indicated that MDMA has a different 
effect profile than other amphetamines. In contrast to MDMA, 
methylphenidate and modafinil increased misclassifications 
of emotions as angry on the FERT while MDMA increased 
misclassifications as happy (39). This is in line with another 
study showing that methylphenidate, but not MDMA, increased 
ratings of sexual arousal for explicit sexual stimuli (80). Neither 
MDMA nor methylphenidate altered appraisal of romantic 
relationships (80). Furthermore, methylphenidate lacked the 
empathy enhancing properties of MDMA (51). When compared 
with methamphetamine, Bershad et al. (37) showed that MDMA, 
but not methamphetamine, enhanced ratings of pleasantness 
of experienced affective touch and increased attention toward 
happy faces. These results indicate that the dopaminergic system, 
but not serotonergic neurotransmission may be involved in 
enhancing sexual drive, whereas the serotonin system may be 
involved in increasing empathy.
To illuminate the pharmacology of GHB-induced prosocial 
effects, one study investigated the relationship between 
GHB-induced alterations in outcomes on social tasks and 
neuroendocrine effects (41). No correlations were found between 
GHB-induced neuroendocrine effects and social behavior, but 
low progesterone levels at baseline were predictive of altruistic 
behavior on the SVO and a Charity Donation Task after GHB 
administration. This indicates that GHB induced prosocial 
behavior specifically in individuals with low progesterone 
levels (41).
Hallucinogens have been reported to exert their prosocial 
effects predominantly via agonism at the 5-HT2A receptor and 
potentially in parallel with downstream effects on aspartate 
metabolism (11). Decreased recognition of negative emotions 
induced by psilocybin on the RMET was blocked by pretreatment 
with the 5-HT2A receptor antagonist ketanserin (51). In line with 
this, LSD-induced effects on joint attention processing, self/other 
differentiation, and social influence processing were blocked by 
ketanserin (34, 84). Comparing the effects of psilocybin to those of 
the N-methyl-d-aspartate receptor antagonist ketamine, Schmidt 
et al. (57) reported differential effects, with psilocybin reducing 
the processing of negative faces, whereas ketamine induced an 
emotional blunting characterized by reduced encoding of both, 
negative and positive facial expressions.
Given these pharmacological results as well as the similarity 
of effects induced by MDMA and hallucinogens, it is conceivable 
that prosocial effects, in particular increased empathy and 
altruistic behavior, are modulated by a common mechanism, 
namely 5-HT2A receptor stimulation. However, the functional 
and modulatory contribution of other receptors stimulated by 
these substances is scarcely investigated, in particular with regard 
to hallucinogens. Additional studies are needed that investigate 
the role of these receptor systems by selectively blocking them 
to comprehensively uncover the neuropharmacology underlying 
hallucinogen-induced modulations of social cognition. GHB 
which targets mainly GHB and GABAB receptors has a different 
effect profile implicating these receptors together with the 
dopamine system in prosexual effects. It has to be noted that 
entactogens and hallucinogens are not the only psychoactive 
substances that modulate social cognitive functioning. For 
example, alcohol has been reported to facilitate social interaction 
(105). While this is beyond the scope of the current review, 
the differential effects hallucinogens, entactogens, and other 
psychoactive substances should be discussed in future articles to 
systematically increase our understanding of the pharmacology 
of social cognition.
CONCLUSION
The current literature on experimental and controlled 
investigations of the influence of hallucinogens and entactogens 
shows that these substances are potent modulators of social 
cognition and behavior. While MDMA is recreationally used for 
its prosocial effects, this review shows that hallucinogens such as 
LSD and psilocybin similarly impact social cognitive measures. 
GHB, however, has been shown to have predominantly prosexual 
effects and may therefore not be classified as a typical entactogen. 
As described in detail in Neuropharmacological Underpinnings 
of Alterations in Social Cognition Induced by Hallucinogens and 
Entactogens, agonism on the 5-HT2A receptor may be a common 
mechanism of classic hallucinogens and MDMA which underlies 
their prosocial effects. This is particularly important for the 
development of highly needed novel therapeutics targeting 
social deficits in psychiatric patients. Furthermore, these results 
implicate alterations in social processing as key mechanisms 
for the efficacy of psilocybin- and MDMA-assisted therapeutic 
approaches. In addiction disorders, the reinstatement of social 
reward processing may support reductions in drug intake and 
help overcome addiction. In anxiety and mood disorders, MDMA 
and hallucinogens may promote re-connection with patients’ 
social environment as well as support seeking and reductions 
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in social withdrawal. Acutely, MDMA and hallucinogens may 
also enhance the patient-therapist relationship. Thus, it is vital 
that therapists working with MDMA and hallucinogens are 
aware of the acute effects of these substances on social cognition, 
including potential increases in suggestibility.
Despite recent efforts to elucidate the effects of hallucinogens 
and entactogens on social cognition, major knowledge gaps 
remain. Studies specifically investigating the dose-dependency 
of modulations in social cognition induced by hallucinogens and 
entactogens are still scarce, in particular regarding psilocybin. 
LSD and MDMA have shown some dose-dependent effects on 
empathy and altruistic behavior (10, 33, 51), indicating that robust 
modulations are measurable at doses of 100 mg MDMA/100µg 
LSD and above. Controlled studies on very low doses, so-called 
“microdoses,” are still rare. Bershad et al. (63) did not find an 
effect of doses <30 µg LSD on social rejection sensitivity and 
emotional face identification. Further studies investigating dose-
dependency in within-subject designs are needed. Furthermore, 
the impact of hallucinogens other than LSD and psilocybin on 
social cognition has not yet been investigated. Sex-specific effects 
are poorly understood. It has been shown that MDMA enhances 
emotional empathy predominantly in male participants (10). 
Furthermore, altruistic behavior after psilocybin administration 
was only investigated in males (66). Despite their potential clinical 
relevance, further systematic investigations into sex-specific 
drug effects are lacking. Data on effects after the acute phase 
of substance action are often missing. The neural mechanisms 
underlying changes in social cognition after administration 
of hallucinogens and entactogens are poorly understood. 
Differential effects of specific receptor systems targeted by these 
substances need to be investigated. Objective data on social 
behavior within the framework of MDMA- and hallucinogen-
assisted therapy are still lacking. Studies on entactogens and 
hallucinogens have consistently shown prosocial effects and have 
identified alterations in social processing and behavior as key 
factors for the efficacy of treatments involving these substances. 
Thus, investigating these questions is a promising way to increase 
our mechanistic, neuropharmacological understanding of social 
processes, advance the development of novel therapeutics, and to 
uncover the full potential of these substances in clinical contexts.
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